According to our classification of TP53 mutations, the age at diagnosis of Group B was lower in breast and bladder cancers, and interestingly, it was higher in tumours of the haematopoietic system compared to Group A and C. The frequency of R213* and Q192* was also increased in breast, as well as R306* and Q192* mutations frequency in bladder cancer. Here, TP53 is linked to urinary bladder cancer.